Abstract
The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding αβ TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.
Original language | English (US) |
---|---|
Pages (from-to) | 5451-5458 |
Number of pages | 8 |
Journal | Journal of Immunology |
Volume | 192 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2014 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology